Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

Diabetes Associated Peptide Amide human - ≥97% (HPLC), high purity , CAS No.122384-88-7, Agonist of AMY 1 receptor;Agonist of AMY 2 receptor;Agonist of AMY 3 receptor;Agonist of CT receptor

Item Number
D118757
Grouped product items
SKUSizeAvailabilityPrice Qty
D118757-1mg
1mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$315.90
D118757-5mg
5mg
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$979.90
Add to Wish List Compare
Bulk Order  SDS  DATASHEET

Endogenous peptide. Potent amylin, calcitonin, CGRP and adrenomedullin receptor agonist.

View related series
AMY1 receptor Agonist AMY2 receptor Agonist AMY3 receptor Agonist CT receptor Agonist

Basic Description

Specifications & PurityMoligand™, ≥97%(HPLC)
Biochemical and Physiological MechanismsIslet amyloid polypeptide (IAPP) is a hormone coexpressed with insulin by pancreatic β-cells. IAPP is used to study the mechanisms of amyloid deposition and its role in molecular misfolding processes expecially in conditions such as diabetes type II.Endog
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Action TypeAGONIST
Mechanism of actionAgonist of AMY 1 receptor;Agonist of AMY 2 receptor;Agonist of AMY 3 receptor;Agonist of CT receptor
NoteWherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one week. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description

Amino Acid Sequence Lys-Cys-Asn-Thr-Ala-Thr-C?ys-Ala-Thr-Gln-Arg-Leu-Al?a-Asn-Phe-Leu-Val-His-Ser?-Ser-Asn-Asn-Phe-Gly-Ala-?Ile-Leu-Ser-Ser-Thr-Asn-V?al-Gly-Ser-Asn-Thr-Tyr-NH?2

Associated Targets(Human)

RAMP2 Tclin Receptor activity-modifying protein 2 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
RAMP1 Tclin Receptor activity-modifying protein 1 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
RAMP3 Tclin Receptor activity-modifying protein 3 (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
CALCR Tclin Calcitonin receptor (0 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Names and Identifiers

IUPAC Name N-[1-[[1-[[1-[[4-amino-1-[[1-[[1-[[1-[[1-[[1-[[1-[[4-amino-1-[[4-amino-1-[[1-[[2-[[1-[[1-[[1-[[1-[[1-[[1-[[4-amino-1-[[1-[[2-[[1-[[4-amino-1-[[1-[[1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]-2-[[2-[2-[[16-(2-amino-2-oxoethyl)-19-(2,6-diaminohexanoylamino)-7,13-bis(1-hydroxyethyl)-10-methyl-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]amino]propanoylamino]-3-hydroxybutanoyl]amino]pentanediamide
INCHI InChI=1S/C165H261N51O55S2/c1-22-75(12)124(159(266)200-95(47-71(4)5)140(247)203-108(64-219)153(260)206-110(66-221)154(261)216-129(84(21)226)163(270)202-105(58-119(174)234)147(254)209-122(73(8)9)157(264)181-61-121(236)187-106(62-217)150(257)198-103(56-117(172)232)148(255)215-128(83(20)225)162(269)190-93(130(175)237)49-87-38-40-89(227)41-39-87)211-132(239)76(13)183-120(235)60-180-136(243)97(50-85-32-25-23-26-33-85)194-144(251)101(54-115(170)230)196-145(252)102(55-116(171)231)197-151(258)107(63-218)205-152(259)109(65-220)204-142(249)99(52-88-59-178-69-182-88)201-158(265)123(74(10)11)210-146(253)96(48-72(6)7)193-141(248)98(51-86-34-27-24-28-35-86)195-143(250)100(53-114(169)229)191-131(238)77(14)184-139(246)94(46-70(2)3)192-137(244)91(37-31-45-179-165(176)177)188-138(245)92(42-43-113(168)228)189-161(268)126(81(18)223)212-133(240)78(15)185-155(262)111-67-272-273-68-112(207-135(242)90(167)36-29-30-44-166)156(263)199-104(57-118(173)233)149(256)214-125(80(17)222)160(267)186-79(16)134(241)213-127(82(19)224)164(271)208-111/h23-28,32-35,38-41,59,69-84,90-112,122-129,217-227H,22,29-31,36-37,42-58,60-68,166-167H2,1-21H3,(H2,168,228)(H2,169,229)(H2,170,230)(H2,171,231)(H2,172,232)(H2,173,233)(H2,174,234)(H2,175,237)(H,178,182)(H,180,243)(H,181,264)(H,183,235)(H,184,246)(H,185,262)(H,186,267)(H,187,236)(H,188,245)(H,189,268)(H,190,269)(H,191,238)(H,192,244)(H,193,248)(H,194,251)(H,195,250)(H,196,252)(H,197,258)(H,198,257)(H,199,263)(H,200,266)(H,201,265)(H,202,270)(H,203,247)(H,204,249)(H,205,259)(H,206,260)(H,207,242)(H,208,271)(H,209,254)(H,210,253)(H,211,239)(H,212,240)(H,213,241)(H,214,256)(H,215,255)(H,216,261)(H4,176,177,179)
InChi Key PLOPBXQQPZYQFA-UHFFFAOYSA-N
Canonical SMILES CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)N)NC(=O)C(C)NC(=O)CNC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC3=CN=CN3)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C5CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N5)C(C)O)C)C(C)O)CC(=O)N)NC(=O)C(CCCCN)N
Isomeric SMILES CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(CO)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)NC(CC(=O)N)C(=O)NC(C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC(=O)N)C(=O)NC(C(C)O)C(=O)NC(CC1=CC=C(C=C1)O)C(=O)N)NC(=O)C(C)NC(=O)CNC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC(=O)N)NC(=O)C(CC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC3=CN=CN3)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=CC=C4)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(C(C)O)NC(=O)C(C)NC(=O)C5CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N5)C(C)O)C)C(C)O)CC(=O)N)NC(=O)C(CCCCN)N
WGK Germany 3
PubChem CID 16158170
Molecular Weight 3903.28

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

4 results found

Lot NumberCertificate TypeDateItem
L1804193Certificate of AnalysisSep 21, 2022 D118757
L1804192Certificate of AnalysisSep 21, 2022 D118757
I1425085Certificate of AnalysisJul 19, 2022 D118757
E1430001Certificate of AnalysisMar 29, 2022 D118757

Safety and Hazards(GHS)

WGK Germany 3

Related Documents

 SDS

 Specification Sheet

References

1. Majumder P et al..  (2021)  A nexus of miR-1271, PAX4 and ALK/RYK influences the cytoskeletal architectures in Alzheimer's Disease and Type 2 Diabetes..  Biochem J,  478  (17): (3297-3317).  [PMID:34409981]
2. Majumder P et al..  (2019)  Receptor tyrosine kinases (RTKs) consociate in regulatory clusters in Alzheimer's disease and type 2 diabetes..  Mol Cell Biochem,  459  (1-2): (171-182).  [PMID:31154588]
3. Suzuki H & Yamamoto T.  (2014)  Amylin-like immunoreactivity in pancreatic X cells of the black-spotted frog Rana (Pelophylax) nigromaculata..  Tissue Cell,  46  (6): (535-9).  [PMID:25458814]
4. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB.  (1987)  Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients..  Proc Natl Acad Sci USA,  84  (23): (8628-32).  [PMID:3317417]
5. Jaikaran ET, Clark A.  (2001)  Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology..  Biochim Biophys Acta,  1537  (3): (179-203).  [PMID:11731221]
6. Ravi Prakash Reddy Nanga,Jeffrey R Brender,Jiadi Xu,Gianluigi Veglia,Ayyalusamy Ramamoorthy.  (2008-11-08)  Structures of rat and human islet amyloid polypeptide IAPP(1-19) in micelles by NMR spectroscopy..  Biochemistry,  47  ((48)): (12689-12697).  [PMID:18989932]
7. Allam S Reddy,Lu Wang,Sadanand Singh,Yun L Ling,Lauren Buchanan,Martin T Zanni,James L Skinner,Juan J de Pablo.  (2010-10-07)  Stable and metastable states of human amylin in solution..  Biophysical journal,  99  ((7)): (2208-2216).  [PMID:20923655]
8. A Clark,M R Nilsson.  (2004-01-15)  Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes?.  Diabetologia,  47  ((2)): (157-169).  [PMID:14722650]
9. Ravi Prakash Reddy Nanga,Jeffrey R Brender,Subramanian Vivekanandan,Ayyalusamy Ramamoorthy.  (2011-07-05)  Structure and membrane orientation of IAPP in its natively amidated form at physiological pH in a membrane environment..  Biochimica et biophysica acta,  1808  ((10)): (2337-2342).  [PMID:21723249]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.